Every Form 4 that Heron Therapeutics, Inc. (HRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRTX filings page.
Heron Therapeutics, Inc. reported insider equity activity by Chief Operating Officer Mark Earl Hensley on August 6, 2026. He exercised 31,250 Restricted Stock Units, receiving an equivalent number of common shares. In a related transaction, 8,888 common shares were delivered or withheld for payment of exercise price or tax liability at $0.5000 per share. Following the transaction, he continued to hold 343,750 Restricted Stock Units representing additional contingent rights to common shares.
Heron Therapeutics (HRTX) Chief Operating Officer Mark Earl Hensley reported the vesting and conversion of 11,769 Restricted Stock Units into 11,769 shares of common stock on July 31, 2026. His direct common stock holdings increased to 148,539 shares, while 164,776 Restricted Stock Units remain outstanding from a 188,315-unit grant dated January 30, 2026, which vests in 16 equal quarterly installments. Each RSU represents a contingent right to receive one share of common stock.
Heron Therapeutics EVP and Chief Development Officer William P. Forbes converted a total of 23,463 restricted stock units into an equal number of common shares on July 30–31, 2026, under time-based vesting schedules. To cover exercise price or tax obligations, 6,674 shares of common stock were withheld at $0.50 per share.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported equity compensation activity involving restricted stock units that settled into common stock on July 30 and 31, 2026. In total, 25,229 RSUs converted into an equal number of common shares, while 7,176 shares were withheld at $0.50 per share in transactions reported under code F for payment of exercise price or tax liability. The RSUs include a 216,562-unit grant awarded on January 30, 2026 that vests in 16 equal quarterly installments beginning one quarter after the grant date, as well as an earlier grant from January 31, 2025 with the same 16-installment vesting structure.
Heron Therapeutics CEO Craig A. Collard exercised previously granted restricted stock units into common stock in late July 2026. On July 30 he converted 50,021 RSUs, and on July 31 he converted 34,789 RSUs, each on a one-for-one basis at a stated price of $0.00 per share. The RSUs vest in 16 equal quarterly installments beginning one quarter after their respective grant dates in January 2025 and January 2026.
Heron Therapeutics, Inc. CEO Craig A. Collard exercised 13,797 restricted stock units into 13,797 shares of common stock on 2026-07-19. After this derivative conversion, he directly holds 771,682 common shares and 82,781 restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.
Heron Therapeutics executive William P. Forbes, EVP and Chief Development Officer, reported equity compensation activity on July 19, 2026. He exercised 3874 restricted stock units into common stock, and 1101 shares of common stock were disposed of in a tax-withholding transaction at $0.47 per share. Following these transactions, he directly owned 225485 shares of common stock and held 23246 restricted stock units.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported equity compensation activity involving restricted stock units (RSUs). On July 19, 2026, 3,874 RSUs converted into common stock, and 1,101 shares were withheld at $0.47 per share for taxes. After these transactions, filings show 263,846 common shares held directly and 23,246 restricted stock units remaining, as part of an award that vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics EVP and CFO Ira Duarte reported routine equity compensation activity. On June 16, 2026, Duarte exercised 12,500 restricted stock units, converting them into common shares at $0.00 per share. To cover tax obligations, 3,555 common shares were disposed of at $0.38 per share. Following these transactions, Duarte directly holds 261,073 shares of common stock and 12,500 restricted stock units, reflecting a compensation-driven change rather than an open-market trade.
Heron Therapeutics EVP William P. Forbes exercised restricted stock units into common shares as part of his compensation. On June 6, 2026, he acquired 12,500 shares of common stock from RSUs at no cash cost. Following the transaction, he directly holds 221,611 common shares and 12,500 RSUs that vest in four equal annual installments, subject to continued service.
Heron Therapeutics Chief Operating Officer Mark Earl Hensley exercised equity awards and increased his direct share holdings. On May 6, 2026, he exercised derivative securities to acquire 125,000 shares of common stock, reflecting the settlement of restricted stock units as equity compensation rather than a cash purchase.
Following the transaction, he directly holds 136,770 shares of common stock and 375,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests 25% on the first anniversary of the grant date of May 6, 2025, then in twelve equal quarterly installments thereafter.
Heron Therapeutics Chief Operating Officer Mark Earl Hensley reported an automatic RSU conversion into common stock. On April 30, 2026, 11,770 restricted stock units converted into 11,770 shares of common stock at a stated price of $0.00 per share, leaving him with 11,770 common shares directly held.
The derivative section shows 11,770 RSUs converted into common stock and 176,545 restricted stock units remaining after the transaction. A prior grant on January 30, 2026 awarded 188,315 RSUs, scheduled to vest in 16 equal quarterly installments beginning one quarter after the grant date.
Heron Therapeutics EVP and Chief Development Officer William P. Forbes exercised restricted stock units into common shares. On April 30, 2026, he exercised awards covering 23,464 shares of common stock in two transactions. Following these exercises, he directly holds 209,111 shares of common stock and 128,638 restricted stock units, which each represent a contingent right to receive one share of common stock. The RSUs vest in 16 equal quarterly installments under time-based schedules beginning one quarter after their respective grant dates.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units into common shares in a compensation-related transaction. On April 30, 2026, Duarte converted 13,535 and 11,694 restricted stock units into the same number of Heron Therapeutics common shares, with no open-market sales reported. Footnotes explain each restricted stock unit represents a right to receive one common share and that 216,562 RSUs granted in January 2026 vest in 16 equal quarterly installments, highlighting an ongoing, time-based equity compensation program.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common stock in a compensation-related transaction. He acquired 50,021 shares and 34,789 shares of common stock upon conversion of RSUs, reflecting previously granted equity awards that vest over time rather than open-market purchases or sales. Collard’s RSU program includes a grant of 800,337 units that vest in 16 equal quarterly installments beginning after the January 30, 2026 date of grant. Footnotes also note 11,023 shares acquired under the company’s Employee Stock Purchase Plan on April 30, 2026.
Heron Therapeutics executive William P. Forbes exercised restricted stock units into common shares in a routine compensation-related move. On April 19, 2026, he converted 3,874 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share, reflecting vesting rather than an open-market purchase or sale.
Following this transaction, Forbes directly held 185,647 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock, and the units vest in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common shares as part of his equity compensation. He converted 13,797 restricted stock units into 13,797 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 662,052 shares of common stock and 96,758 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units to receive additional common shares as equity compensation. On this date, 3,874 restricted stock units converted into 3,874 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Duarte directly held 215,876 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
A footnote also notes that Duarte’s holdings include 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025, highlighting ongoing participation in both stock purchase and equity award programs.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised 62,500 restricted stock units into 62,500 shares of common stock. The RSUs carried a $0.0000 exercise price and each unit represented a right to receive one share of common stock.
After the transaction, Collard directly owned 648,255 shares of Heron Therapeutics common stock. His holdings include 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. The restricted stock units vest in four equal annual installments beginning one year after the grant date, contingent on his continued service.
Heron Therapeutics Chief Executive Officer Craig A. Collard reported new equity awards. On January 30, 2026, he received 800,337 restricted stock units (RSUs), which each convert into one share of common stock and vest in 16 equal quarterly installments starting one quarter after the grant date.
He was also granted 800,336 performance stock units (PSUs), each convertible into one share of common stock. These PSUs vest on the same 16-quarter schedule, but only to the extent a milestone is met based on a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K.
Heron Therapeutics director Christian Waage received a new equity award in the form of restricted stock units. On January 30, 2026, he was granted 53,960 shares of common stock at a price of $0 per share.
The award was structured as restricted stock units that vest in full on January 30, 2027, with each unit representing the right to receive one share of common stock. Following this grant, Waage beneficially owned 53,960 shares directly.
Heron Therapeutics, Inc. director Michael Kaseta reported an equity award. On January 30, 2026, he received 53,960 shares of common stock in the form of restricted stock units at a price of $0 per share. These units vest in full on January 30, 2027, with each unit delivering one share. Following this grant, he beneficially owns 53,960 shares directly.
Heron Therapeutics EVP and CFO Ira Duarte received new equity awards. On January 30, 2026, Duarte was granted 216,562 restricted stock units (RSUs) and 216,561 performance stock units (PSUs), each convertible into common stock on a one-for-one basis.
The RSUs vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs follow the same quarterly schedule but also depend on achieving a net product sales revenue target for fiscal 2026 as reported in the company’s Form 10-K.
Heron Therapeutics director Craig A. Johnson received a grant of 53,960 shares of common stock in the form of restricted stock units. The grant was made on January 30, 2026 at a price of $0 per share, reflecting an equity award rather than an open-market purchase.
The restricted stock units vest in full on January 30, 2027, at which point each unit will convert into one share of common stock. After this grant, Johnson is reported as directly beneficially owning 53,960 shares of Heron Therapeutics common stock.
Heron Therapeutics director Thomas Cusack received an equity award of 53,960 shares of common stock on January 30, 2026. The award was granted as restricted stock units at a price of $0 per share, bringing his directly owned holdings to 53,960 shares.
The restricted stock units vest in full on January 30, 2027, and each unit represents a contingent right to receive one share of Heron Therapeutics common stock once vested. This reflects stock-based director compensation rather than an open‑market purchase.
Heron Therapeutics executive William P. Forbes reported new equity awards. On January 30, 2026, the EVP and Chief Development Officer received 188,315 restricted stock units and 188,314 performance stock units, both at a price of $0 per unit and held directly.
The RSUs convert into common stock on a one-for-one basis and vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs also vest in 16 equal quarterly installments, but only if a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K, is achieved.
Heron Therapeutics director Sharmila Dissanaike received a grant of 53,960 restricted stock units of common stock. The units were awarded at a price of $0 per share, so she did not pay cash for this equity grant.
The award vests in full on January 30, 2027. Each restricted stock unit represents the right to receive one share of Heron Therapeutics common stock when it vests, giving her 53,960 shares beneficially owned directly after the grant.
Heron Therapeutics (HRTX) granted new equity awards to its Chief Operating Officer, Mark Earl Hensley. On January 30, 2026, he received 188,315 restricted stock units (RSUs) and 188,314 performance stock units (PSUs), each convertible into common stock on a one-for-one basis.
The RSUs vest in 16 equal quarterly installments starting one quarter after the grant date. The PSUs follow the same quarterly schedule but also depend on achieving a net product sales revenue target for the fiscal year ending December 31, 2026, as reported in the company’s Form 10-K.
Heron Therapeutics director Adam Morgan reported an equity grant and updated holdings. On January 30, 2026, he acquired 53,960 shares of common stock at a price of $0 through restricted stock units that vest in full on January 30, 2027. After this grant, he directly beneficially owns 123,737 shares of common stock.
An additional 8,753,290 shares of common stock are reported as indirectly owned by Velan Capital Master Fund LP. Mr. Morgan may be deemed to beneficially own these securities through related entities but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares. On January 31, 2026, 11,695 restricted stock units were converted into 11,695 shares of common stock at a price of $0 per share under a previously granted equity award.
After this transaction, Duarte directly owned 195,356 shares of common stock and held 140,332 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 16 equal quarterly installments that began on January 31, 2025.
Heron Therapeutics executive William P. Forbes reported the vesting of restricted stock units (RSUs) into common shares. On January 31, 2026, 11,695 RSUs converted into 11,695 shares of common stock at an exercise price of $0.00 per share.
After this transaction, Forbes directly owned 181,773 shares of common stock and 140,332 RSUs. Each RSU represents the right to receive one share of common stock, and the RSUs vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date.
Heron Therapeutics CEO Craig A. Collard, who also serves as a director, reported the vesting and conversion of 34,789 restricted stock units into an equal number of Heron common shares on January 31, 2026 via transaction code M.
Each restricted stock unit represents the right to receive one share of common stock, and these units vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date. Following this transaction, Collard directly holds 571,710 shares of common stock and 417,464 restricted stock units, reflecting his ongoing equity compensation in the company.
Heron Therapeutics executive William P. Forbes reported a routine equity vesting transaction. On 01/19/2026, 3,875 restricted stock units converted into an equal number of shares of Heron Therapeutics common stock, at an exercise price of $0.00 per unit. Following this conversion, Forbes directly held 30,994 restricted stock units and 170,078 shares of common stock. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the original grant date of 01/19/2024, reflecting ongoing equity-based compensation rather than an open-market share sale.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported the vesting of restricted stock units and corresponding acquisition of common stock. On 01/19/2026, 3,875 restricted stock units were converted into 3,875 shares of common stock at a price of $0 per share in a transaction coded "M," which indicates an exercise or conversion. Following this transaction, Duarte directly held 183,661 shares of Heron Therapeutics common stock and 30,994 restricted stock units.
The footnotes explain that each restricted stock unit represents a right to receive one share of common stock and that the units vest in 16 equal quarterly installments starting one quarter after the grant date of 01/19/2024. This reflects routine equity compensation vesting for a senior executive rather than an open-market purchase or sale.
Heron Therapeutics, Inc. Chief Executive Officer Craig A. Collard reported an RSU vesting and share acquisition on 01/19/2026. A total of 13,797 restricted stock units were converted at an exercise price of $0 into 13,797 shares of common stock, reflecting previously granted equity compensation rather than an open-market purchase.
Each restricted stock unit represents a contingent right to receive one share of common stock, and these RSUs vest in 16 equal quarterly installments beginning one quarter after the 01/19/2024 grant date. Following this transaction, Collard directly held 110,375 restricted stock units and 536,921 shares of common stock.
Heron Therapeutics (HRTX) reported a director equity grant. On 11/08/2025, the reporting person acquired 37,879 shares of common stock via restricted stock units, with 37,879 shares beneficially owned following the transaction. Each RSU equals one share and vests in 16 equal quarterly installments beginning one quarter after grant.
On the same date, the director received stock options for 227,272 shares at an exercise price of $1.1, expiring on 11/08/2035. These options vest in 48 equal monthly installments starting one month after grant.
Heron Therapeutics (HRTX): Officer William P. Forbes reported an RSU vesting and settlement. On 10/31/2025, 11,694 shares of common stock were acquired from restricted stock units at a price of $0.00 per share (Transaction Code M). Following this, he beneficially owned 166,203 shares directly. The filing also lists 152,027 restricted stock units remaining after the transaction.
Each restricted stock unit represents the right to receive one share of common stock. The RSUs vest in 16 equal installments beginning one quarter after the grant date, January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction by EVP & Chief Financial Officer Ira Duarte. On 10/31/2025, 11,694 shares of common stock were acquired upon settlement of restricted stock units. After this transaction, 179,786 common shares are beneficially owned directly, and 152,027 restricted stock units remain outstanding. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported an insider transaction: CEO and Director Craig Collard acquired 34,789 shares of common stock on 10/31/2025 through settlement of restricted stock units (transaction code M) at $0.
Following the transaction, Collard directly owned 523,124 shares. He also beneficially owned 452,253 RSUs after the event. The RSUs vest in 16 equal installments beginning one quarter after the grant date of January 31, 2025.
Heron Therapeutics (HRTX) reported an insider equity change. EVP & Chief Development Officer William P. Forbes acquired 3,874 shares of common stock on 10/19/2025 via the conversion of restricted stock units (transaction code M). Following this event, he directly owns 154,509 shares of common stock. The filing also lists 34,869 derivative securities remaining as restricted stock units. Each RSU equals one share, and the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024.
Heron Therapeutics (HRTX) reported an insider equity change by EVP & CFO Ira Duarte on 10/19/2025. A tranche of 3,874 shares of common stock was acquired upon the vesting/settlement of restricted stock units, reflected as a transaction code M.
Following the transaction, Duarte directly beneficially owns 168,092 shares of common stock and 34,869 RSUs. Each RSU represents the right to receive one share of common stock. The RSUs vest in 16 equal quarterly installments beginning one quarter after the grant date of 01/19/2024.
Heron Therapeutics (HRTX) reported an insider equity change by CEO and Director Craig Collard. On 10/19/2025, 13,797 restricted stock units (RSUs) were converted to common stock via transaction code M, resulting in the acquisition of 13,797 shares at $0 per RSU. Following the transaction, 488,335 common shares were beneficially owned directly. The filing notes the RSUs vest in 16 equal quarterly installments beginning one quarter after 01/19/2024. After this event, 124,172 RSUs were directly held.